The Pistoia Alliance, a global, not for profit alliance that works to lower barriers to innovation in life sciences R&D, is calling upon the industry to improve collaborative efforts to use patient data to its full effect. In a series of keynote speeches delivered at The Pistoia Alliance’s annual member conference in London, speakers from Amgen, Accenture and AstraZeneca, discussed the need to more closely connect outcomes data with the R&D process – to help pharmaceutical companies focus their research efforts and deliver real benefits to patients. Building machine learning and deep learning systems, and incorporating data from therapeutic interventions or diagnostics into R&D is technologically challenging, and would benefit significantly from industry-wide pre-competitive collaboration...
Amgen
See the following -
CEO Roundtable On Cancer Launches The Project Data Sphere Initiative, A New Data Sharing And Analytic Platform For Cancer Patient Benefit
Project Data Sphere, LLC (PDS), an independent not-for-profit initiative of the CEO Roundtable on Cancer’s Life Sciences Consortium (LSC), announced today the launch of a new data sharing platform (www.ProjectDataSphere.org), with the goal of advancing research to improve the lives of cancer patients and their families around the world...
- Login to post comments
Doctors Promoting Treatments on Social Media Routinely Fail to Disclose Ties to Drug Makers
Physicians across the United States routinely offer medical advice on social media — but often fail to mention that they have accepted tens and sometimes hundreds of thousands of dollars from the companies that make the prescription drugs they tout. A STAT examination of hundreds of social media accounts shows that health care professionals virtually never note their conflicts of interest, some of them significant, when promoting drugs or medical devices on sites such as Facebook, Instagram, and Twitter. The practice cuts across all specialties...
- Login to post comments
How Flawed Science Is Undermining Good Medicine
A surprising medical finding caught the eye of NPR's veteran science correspondent Richard Harris in 2014. A scientist from the drug company Amgen had reviewed the results of 53 studies that were originally thought to be highly promising — findings likely to lead to important new drugs. But when the Amgen scientist tried to replicate those promising results, in most cases he couldn't...
- Login to post comments
Is the American Heart Association a Terrorist Organization?
A few days ago, the AHA stole the attention of headlines across the globe with a report that sounded like it was straight out of the 1990s: Dietary Fats and Cardiovascular Disease: A Presidential Advisory From the American Heart Association. In this report, the AHA doubled down on their attacks against coconut oil and saturated fat. Frank Sacks, lead author on the report, reportedly said that he has no idea why people think coconut oil is healthy...
- Login to post comments
Mylan Isn't Alone: 11 Drugmakers with Off-the-Charts Pricing Power
Mylan (MYL) is drawing fire for passing off massive price hikes for its EpiPen allergy treatment. But it’s far from being the drug company with the most pricing power. Gilead (GILD), Biogen (BIIB) and Amgen (AMGN), along with eight other drug giants in the Standard & Poor's 500, enjoyed off-the-charts pricing power on their products relative to costs — far beyond Mylan's, according to a USA TODAY analysis of data from S&P Global Market Intelligence...
- Login to post comments
Public Research For Private Gain
UC Regents recently approved a new corporate entity that will likely give a group of well-connected businesspeople control over how academic research is used. Read More »
- Login to post comments
The Pistoia Alliance Calls on the Life Sciences to Support Greater Collaboration to Overcome Technology Challenges
- Login to post comments
You Won't Believe the Outrageous Ways Big Pharma Has Bribed Doctors to Shill Drugs
At the 2010 meeting of the American Psychiatric Association in New Orleans, a psychiatrist from the East coast shared her anger with me about the recent clamp down on Pharma financial perks to doctors. Before news organizations and the 2010 Physician Financial Transparency Reports (also called the Sunshine Act, part of the Affordable Care Act) reported the outrageous amount of money Pharma was giving doctors to prescribe its new, brand-name drugs, there was almost no limit to what was spent to encourage prescribing...
- Login to post comments